Get the tools and support you need to best manage your eczema

  • This field is for validation purposes and should be left unchanged.

News

Bust out that yoga mat because researchers are getting closer to understanding the benefits of stress reduction for inflammatory skin diseases. April 18, 2017 – By Kathryn Jones Whether it’s acne, hives or an eczema flare, we know that stress and anxiety can cause a visible reaction in our skin. Doctors understand a link exists […]

Read More


April 18, 2017 Tips for getting a handle on one of eczema’s most annoying symptom areas—the hands Our hands are among the worst body parts to develop an eczema rash, hands down (excuse the pun) because we rely on them so heavily to perform basic everyday tasks. Itchy, painful rashes are more distracting and seem […]

Read More


March 28, 2017 – Today, the U.S. Food and Drug Administration approved Dupixent (dupilumab), the first biologic medication for adults with moderate to severe atopic dermatitis (AD) for whom other topical treatments have not worked or are not advised. Different from topical or oral medications, biologic drugs or “biologics” are made from proteins typically derived […]

Read More


March 21, 2017 – Our skin is covered in a web of billions of tiny organisms including bacteria, viruses and fungi. This web is called the skin microbiome and when healthy, helps our bodies function properly inside and out. Researchers have long known that people with atopic dermatitis (AD) have different skin biology than those […]

Read More


March 21, 2017 – Earlier this month, Republican leaders in the House of Representatives introduced the American Health Care Act (AHCA) to replace the Affordable Health Care Act (ACA) passed in March 2010. The ACA, also known as Obamacare, has several key components that protects access to health care for people with pre-existing conditions and/or chronic […]

Read More


Each year, thousands of doctors, scientists, students, industry and patient advocacy groups like National Eczema Association, gather to hear the latest research and standards of medical care in dermatology at the American Academy of Dermatology (AAD) Annual Meeting. Atopic dermatitis is a hot field of study. Here’s some highlights from this year’s AAD meeting. Biologic […]

Read More


February 21, 2017 — There are dozens of new drugs in development for atopic dermatitis (AD). Late last year, the Food and Drug Administration (FDA) approved the non-steroidal topical treatment, Eucrisa for mild to moderate atopic dermatitis. This March, the FDA is expected to approve dupilumab, the first biologic drug for adults with moderate to […]

Read More


Pain and poor sleep – two symptoms common to people with atopic dermatitis. When these symptoms spin out of control, every part of one’s life is impacted. To find out more about why and how pain and sleep problems affect people with atopic dermatitis, the National Eczema Association funded three studies in these areas as […]

Read More


January 17, 2017 — Biologic drugs have been making headlines as potentially promising new therapies for treating atopic dermatitis (AD). Several have shown positive results in clinical trials and one, dupilumab, is being reviewed for approval by the Food and Drug Administration (FDA) and is expected to come to market in 2017. Biologic medications are […]

Read More


January 17, 2017 — For the first time, ever, the Institute for Clinical and Economic Review (ICER) has begun a process to review the clinical effectiveness and value of two new treatments for atopic dermatitis (AD). ICER is an independent, nonprofit organization that evaluates treatments for serious diseases such as cancer, multiple sclerosis and psoriasis, […]

Read More